With multiple medications approved to treat multiple sclerosis there is more work being done to help a larger patient population through the course of disease treatment.

While there is work being done to develop new treatments, Kate Dawson, MD, from Biogen said the company is working on new potential treatment methods in addition to finding new applications for its medications on the market today. Dawson, speaking at the annual ECTRIMS meeting in London said they are looking specifically at remylination in addition to other potential alternatives.